vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and PARKE BANCORP, INC. (PKBK). Click either name above to swap in a different company.

PARKE BANCORP, INC. is the larger business by last-quarter revenue ($22.7M vs $14.7M, roughly 1.5× IRIDEX CORP). On growth, PARKE BANCORP, INC. posted the faster year-over-year revenue change (35.7% vs -69.7%). Over the past eight quarters, PARKE BANCORP, INC.'s revenue compounded faster (22.6% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Parke Bancorp, Inc. is a U.S. regional bank holding company operating Parke Bank. It offers commercial and retail banking services including deposit products, mortgage loans, small business financing and personal lending, primarily serving customers across New Jersey and the Philadelphia metropolitan area.

IRIX vs PKBK — Head-to-Head

Bigger by revenue
PKBK
PKBK
1.5× larger
PKBK
$22.7M
$14.7M
IRIX
Growing faster (revenue YoY)
PKBK
PKBK
+105.4% gap
PKBK
35.7%
-69.7%
IRIX
Faster 2-yr revenue CAGR
PKBK
PKBK
Annualised
PKBK
22.6%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
PKBK
PKBK
Revenue
$14.7M
$22.7M
Net Profit
$11.1M
Gross Margin
37.2%
Operating Margin
64.2%
Net Margin
48.8%
Revenue YoY
-69.7%
35.7%
Net Profit YoY
49.8%
EPS (diluted)
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
PKBK
PKBK
Q4 25
$14.7M
$22.7M
Q3 25
$12.5M
$21.0M
Q2 25
$13.6M
$18.7M
Q1 25
$11.9M
$17.4M
Q4 24
$12.7M
$16.8M
Q3 24
$11.6M
$15.6M
Q2 24
$12.6M
$15.5M
Q1 24
$11.8M
$15.1M
Net Profit
IRIX
IRIX
PKBK
PKBK
Q4 25
$11.1M
Q3 25
$-1.6M
$10.6M
Q2 25
$-994.0K
$8.3M
Q1 25
$-1.7M
$7.8M
Q4 24
$-834.0K
$7.4M
Q3 24
$-1.9M
$7.5M
Q2 24
$-2.7M
$6.5M
Q1 24
$-3.5M
$6.2M
Gross Margin
IRIX
IRIX
PKBK
PKBK
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
PKBK
PKBK
Q4 25
64.2%
Q3 25
-11.3%
64.2%
Q2 25
-6.9%
59.0%
Q1 25
-1.7%
59.1%
Q4 24
-3.9%
58.0%
Q3 24
-16.1%
60.2%
Q2 24
-20.9%
56.7%
Q1 24
-28.0%
55.4%
Net Margin
IRIX
IRIX
PKBK
PKBK
Q4 25
48.8%
Q3 25
-12.6%
50.6%
Q2 25
-7.3%
44.3%
Q1 25
-14.2%
44.6%
Q4 24
-6.6%
44.2%
Q3 24
-16.7%
48.1%
Q2 24
-21.2%
41.6%
Q1 24
-29.5%
40.7%
EPS (diluted)
IRIX
IRIX
PKBK
PKBK
Q4 25
$0.93
Q3 25
$-0.09
$0.89
Q2 25
$-0.06
$0.69
Q1 25
$-0.10
$0.65
Q4 24
$-0.05
$0.61
Q3 24
$-0.12
$0.62
Q2 24
$-0.16
$0.53
Q1 24
$-0.21
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
PKBK
PKBK
Cash + ST InvestmentsLiquidity on hand
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$324.5M
Total Assets
$29.2M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
PKBK
PKBK
Q4 25
$6.0M
Q3 25
$5.6M
Q2 25
$6.8M
Q1 25
$7.2M
Q4 24
$2.4M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
PKBK
PKBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
PKBK
PKBK
Q4 25
$324.5M
Q3 25
$4.7M
$314.8M
Q2 25
$6.1M
$312.2M
Q1 25
$852.0K
$305.9M
Q4 24
$2.1M
$300.1M
Q3 24
$2.6M
$296.5M
Q2 24
$4.2M
$292.8M
Q1 24
$6.5M
$288.4M
Total Assets
IRIX
IRIX
PKBK
PKBK
Q4 25
$29.2M
$2.2B
Q3 25
$28.4M
$2.2B
Q2 25
$31.6M
$2.2B
Q1 25
$34.2M
$2.1B
Q4 24
$29.1M
$2.1B
Q3 24
$30.2M
$2.1B
Q2 24
$31.2M
$2.0B
Q1 24
$34.1M
$2.0B
Debt / Equity
IRIX
IRIX
PKBK
PKBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
PKBK
PKBK
Operating Cash FlowLast quarter
$39.6M
Free Cash FlowOCF − Capex
$39.0M
FCF MarginFCF / Revenue
171.3%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
3.57×
TTM Free Cash FlowTrailing 4 quarters
$63.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
PKBK
PKBK
Q4 25
$39.6M
Q3 25
$-1.2M
$11.4M
Q2 25
$-397.0K
$6.8M
Q1 25
$-1.1M
$7.0M
Q4 24
$-1.2M
$35.2M
Q3 24
$-3.1M
$9.4M
Q2 24
$-1.3M
$8.9M
Q1 24
$-1.6M
$8.3M
Free Cash Flow
IRIX
IRIX
PKBK
PKBK
Q4 25
$39.0M
Q3 25
$-1.2M
$11.2M
Q2 25
$-410.0K
$6.7M
Q1 25
$-1.2M
$6.6M
Q4 24
$-1.2M
$35.0M
Q3 24
$-3.1M
$9.4M
Q2 24
$8.9M
Q1 24
$-1.7M
$8.3M
FCF Margin
IRIX
IRIX
PKBK
PKBK
Q4 25
171.3%
Q3 25
-9.4%
53.5%
Q2 25
-3.0%
35.8%
Q1 25
-9.8%
38.0%
Q4 24
-9.8%
209.1%
Q3 24
-26.5%
60.0%
Q2 24
57.1%
Q1 24
-14.0%
55.1%
Capex Intensity
IRIX
IRIX
PKBK
PKBK
Q4 25
2.6%
Q3 25
0.1%
0.5%
Q2 25
0.1%
0.3%
Q1 25
0.1%
2.2%
Q4 24
0.1%
0.7%
Q3 24
0.0%
0.1%
Q2 24
0.0%
0.2%
Q1 24
0.0%
0.1%
Cash Conversion
IRIX
IRIX
PKBK
PKBK
Q4 25
3.57×
Q3 25
1.07×
Q2 25
0.82×
Q1 25
0.90×
Q4 24
4.75×
Q3 24
1.25×
Q2 24
1.38×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons